Teva stock targets $6-7 billion in innovative medicines by 2030

Teva Pharmaceutical Industries is raising its long-term ambitions for innovative medicines as Chief Executive Richard Francis presents the company as a broader biopharma business. In an interview with Globes on Thursday, November 12, Francis said Teva has moved beyond its traditional generics profile after the company's R&D Day in New York.

Branded medicines drive the shift

Teva lifted its 2030 revenue target for innovative medicines to $6-7 billion from about $5 billion, according to Globes. The company projects branded products at $3.77-3.92 billion this year, or roughly 20% of total revenue, and expects that share to exceed 25% by 2030.

The strategy has already expanded Teva's branded portfolio from two marketed products in 2022 to four today. Management sees potential for as many as nine branded drugs by 2030, giving investors a clearer measure of the pipeline's intended contribution.

Pipeline execution remains decisive

Francis said Teva expects free cash flow to exceed $3.5 billion by 2030, compared with about $2 billion this year. That outlook supports continued investment in internal research, partnerships and potential business-development opportunities, but it also raises the importance of successful launches and disciplined capital allocation.

Teva's generics and biosimilars operations remain a foundational part of the strategy rather than a business slated for retreat. Francis also said the company is evaluating larger opportunities, while stressing that product fit and valuation would determine any transaction.

US equities provide the broader market backdrop for investors following Teva in the S&P 500.

More news and analyses on Teva stock.